RespireRx Pharmaceuticals Inc (RSPI)

[K-G]

Neuro,

Thanks for the response.

As for Indian companies I was thinking that with the patent law changes in 2005 and the following mass associations of Indian companies with western companies, that there would be some desire from several to buy or partner with Cortex. Ranbaxy has a focus on respiratory disease, which might mean they are interested in RD.

As far as Latin America goes, EMS in Brazil has done original work with benzodiazepines, and seems to have a reasonable development program. They might be interested in acquiring rights to ampakines to broaden their areas of emphasis.

Personally, I think many companies around the world would be happy to pick up Cortex, or license the rights to develop ampakines in specific therapeutic areas - if the price is right. I guess it is just the difference in opinion on what the right price is that is keeping things stalled....